MedTrace Logo

Bone Loss Treatment From Adjuvant Zoledronate Efficacy

NCT01623908 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-06-22

No results posted yet for this study

Summary

The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.

The second purposes:

* The efficacy of adjuvant zoledronate
* The safety of adjuvant zoledronate
* The bone loss of breast cancer patients in Guangdong
* The correlation between bone loss of breast cancer patients and treatment of disease in Guangdong

Conditions

  • Breast Neoplasms
  • Bone Loss

Interventions

DRUG

Zoledronate

4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Shenming Wang, MD, PhD · First Affiliated Hospital, Sun Yat-Sen University

  • Ying Lin, MD, PhD · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623908 on ClinicalTrials.gov